Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, hematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India.

Revenue projections:

Revenue projections for IPCALAB
Revenue projections for IPCALAB

IPCALAB is projected to see a decline in revenue compared to last year, which could lead to investor caution. A drop in earnings is often viewed as a negative signal for profitability, making it more difficult for the company to maintain investor confidence in its financial health.

Financial Ratios:

currentRatio 0.00000
forwardPE 28.23570
debtToEquity 14.42500
earningsGrowth 0.23600
revenueGrowth 0.06600
grossMargins 0.66945
operatingMargins 0.17796
trailingEps 35.82000
forwardEps 54.08047

IPCALAB's Forward PE ratio suggests the stock price is reasonable in relation to earnings. It's not overpriced, providing room for future growth, making the stock a potentially valuable investment for those seeking long-term gains.
Ipca Laboratories Limited's low Debt-to-Equity ratio indicates that the company isn't over-leveraged, suggesting it maintains a healthy balance between debt and equity. This lowers financial risk and points to a stable financial foundation, reassuring investors of the company's financial health.
IPCALAB's forward EPS being higher than its trailing EPS signals anticipated growth in profitability for the current financial year. This suggests that IPCALAB is on track to improve its earnings, outpacing the previous year's performance and reflecting positive market expectations.

Price projections:

Price projections for IPCALAB
Price projections for IPCALAB

IPCALAB's price projections have consistently been revised higher, indicating growing confidence in the company's future potential. Analysts appear more optimistic about IPCALAB's ability to generate strong results going forward.

Insider Transactions:

Insider Transactions for IPCALAB
Insider Transactions for IPCALAB


In recent market activity, 2 sales of IPCALAB shares took place, with market price at 1456.75.There were no sell transactions recorded during the period under consideration.Investors have been purchasing Ipca Laboratories Limited more than selling it at current price levels, which may reflect optimism. This pattern suggests that the market expects favorable outcomes for the stock, leading to increased buying interest.

Recommendation changes over time:

Recommendations trend for IPCALAB
Recommendations trend for IPCALAB


Analysts have been favoring IPCALAB with a buy bias recently, signaling a promising investment opportunity. This optimistic outlook may attract more investors, positioning IPCALAB as a desirable option for those seeking to invest their money in a stable, profitable company with strong growth potential.